Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study Comparing Electrochemotherapy with Bleomycin to Standard Radiotherapy for Treating Basal Cell Carcinoma in Patients with Tumors Less Than 3 cm

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of basal cell carcinoma, a common type of non-melanoma skin cancer. The study will compare two treatments: electrochemotherapy and standard radiotherapy. Electrochemotherapy is a method that combines chemotherapy with electrical pulses to enhance the effect of the drug on cancer cells. The chemotherapy drug used in this study is called Bleomycin, which is administered as a solution for injection or infusion directly into the tumor.

The purpose of the study is to compare the effects of electrochemotherapy with those of standard radiotherapy in treating basal cell carcinomas that are less than 3 cm in size. Participants in the study will receive either electrochemotherapy or radiotherapy, and the effects of these treatments will be observed and compared. The study will also monitor any side effects, the cosmetic outcomes of the treatments, and the satisfaction of the participants with the treatment they receive.

The study will take place over several years, with participants being monitored throughout the treatment process. The goal is to determine which treatment is more effective and to gather information on the overall experience of the participants. This information will help in understanding the best approach to treating basal cell carcinoma in the future.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying that the basal cell carcinoma is less than 3 cm and accessible for both treatments.

    A biopsy is performed to confirm the diagnosis of basal cell carcinoma.

  2. Step 2

    Treatment allocation

    Participants are randomly assigned to one of two treatment groups: electrochemotherapy or standard radiotherapy.

    The allocation is done to compare the effectiveness of the two treatments.

  3. Step 3

    Electrochemotherapy treatment

    For those in the electrochemotherapy group, the treatment involves the use of bleomycin, administered directly into the tumor.

    The medication is given as a solution for injection or infusion, specifically targeting the tumor site.

  4. Step 4

    Standard radiotherapy treatment

    Participants in the standard radiotherapy group receive radiation treatment aimed at the tumor.

    The frequency and duration of the radiotherapy sessions are determined by the study protocol.

  5. Step 5

    Monitoring and follow-up

    Throughout the study, participants are monitored for the effectiveness of the treatment and any adverse events.

    Regular follow-up appointments are scheduled to assess cosmesis (the appearance of the treated area) and patient satisfaction.

  6. Step 6

    Study completion

    The study is estimated to conclude by December 15, 2028.

    Final assessments are conducted to evaluate the primary and secondary endpoints, including the overall effect of the treatments.

Who can join the trial?

4 criteria

  • Must be **18 years or older**.
  • Must have a **biopsy** (a small sample of tissue taken for testing) that confirms **basal cell carcinoma** (a type of skin cancer) that is less than **3 cm** in size and can be treated with both **radiotherapy** (treatment using radiation) and **electrochemotherapy** (a treatment combining electricity and chemotherapy).
  • Must be able to **understand the patient information** provided about the study.
  • Must have **signed informed consent**, which means agreeing to participate in the study after being informed about it.

Who cannot join the trial?

5 criteria

  • Patients with a type of skin cancer called basal cell carcinoma that is larger than 3 cm cannot participate.
  • Patients who have other types of skin cancer, such as melanoma, are not eligible. Melanoma is a more serious form of skin cancer.
  • Patients who are not within the specified age range for the study cannot join. The age range is not specified here, but it is important for eligibility.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, are not allowed to participate.
  • Patients who have any medical condition or situation that the study doctors believe would make it unsafe or inappropriate for them to participate will be excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Electrochemotherapy

    is a treatment that combines chemotherapy with electrical pulses. The electrical pulses help the chemotherapy drugs enter cancer cells more effectively. This method is used to treat basal cell carcinoma, a type of skin cancer, by enhancing the effects of the chemotherapy drugs on the cancer cells.

  • Standard Radiotherapy

    is a common cancer treatment that uses high-energy rays to target and destroy cancer cells. In this trial, it is used as a comparison to electrochemotherapy to see which method is more effective in treating basal cell carcinoma.

What is already known about the treatment

Electrochemotherapy – This treatment is administered through a combination of chemotherapy drugs and electrical pulses directly to the tumor site. It is currently being studied in clinical trials for its effectiveness in treating basal cell carcinoma, a type of non-melanoma skin cancer. The main therapeutic indication is for tumors less than 3 cm in size. The mechanism of action involves enhancing the uptake of chemotherapy drugs into cancer cells by temporarily increasing cell membrane permeability with electrical pulses. It is classified under cancer treatment methods that combine physical and chemical approaches.

Investigated diseases

Basal Cell Carcinoma – Basal cell carcinoma is a type of skin cancer that begins in the basal cells, which are found in the outer layer of the skin. It typically appears as a slightly transparent bump on the skin, though it can take other forms. This cancer is most often caused by long-term exposure to ultraviolet (UV) radiation from sunlight. Basal cell carcinoma grows slowly and is unlikely to spread to other parts of the body. It can cause damage to surrounding tissues if not treated. The condition is more common in areas of the skin that are frequently exposed to the sun, such as the face and neck.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-519066-49-01Estimated enrolment52 patientsSponsorRegion Hovedstaden

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).